Zevra Therapeutics (ZVRA) Receivables (2016 - 2026)

Zevra Therapeutics has reported Receivables for 11 years, with the latest figure at $22.1 million in Q1 2026.

• For the quarter ending Q1 2026, Receivables rose 75.14% year-over-year to $22.1 million; the trailing twelve-month figure through Mar 2026 stood at $22.1 million (up 75.14% YoY), and the FY2025 full-year result was $23.3 million, up 114.52% from the prior year.
• Receivables for Q1 2026 stood at $22.1 million, down from $23.3 million in the prior quarter.
• The five-year high for Receivables was $23.3 million in Q4 2025, with the low at $700000.0 in Q1 2023.
• Historically, Receivables has averaged $11.0 million across 5 years, with a median of $9.4 million in 2022.
• Annual changes were most pronounced in 2023 — Receivables slumped 78.92% — and 2025, when it jumped 1431.0%.
• Zevra Therapeutics' Receivables stood at $9.4 million in 2022, then soared by 97.97% to $18.6 million in 2023, then plunged by 41.82% to $10.8 million in 2024, then soared by 114.52% to $23.3 million in 2025, then dropped by 4.99% to $22.1 million in 2026.
• The last three Receivables figures came in at $22.1 million (Q1 2026), $23.3 million (Q4 2025), and $16.8 million (Q3 2025), per Business Quant data.